Skip to content

Equity

SHSSX

Health Sciences Opportunities Fund

Overview

Loading

Performance

Performance

  • Returns

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Effective as of May 31, 2018, the performance information for periods prior to the inception date of the share class shows the performance of the Fund’s Investor A Shares. The performance of this share class would be substantially similar to Investor A Shares because this share class and Investor A Shares invest in the same portfolio of securities and performance would only differ to the extent that this share class and Investor A Shares have different expenses. For performance periods prior to May 31, 2018, the performance information for periods prior to the inception date of the share class shows the performance of the Fund’s Investor A Shares, adjusted to reflect the fees and expenses applicable to such share class. See the fund prospectus for more details.

Growth of Hypothetical $10,000 The growth of hypothetical $10,000 chart reflects a hypothetical $10,000 investment and assumes reinvestment of dividends and capital gains. Fund expenses, including management fees and other expenses were deducted.

Performance chart data not available for display.
View full chart

Distributions

Interactive chart displaying fund performance. Javascript is required.

View full chart

Key Facts

Key Facts

Size of Class (Millions) as of Oct 14, 2019 $3,075.5 M
Size of Fund (Millions) as of Oct 14, 2019 $6,814.8 M
Share Class launch date Oct 16, 2000
Asset Class Equity
Morningstar Category Health
Lipper Classification Health/Biotech Funds
Benchmark Index Russell 3000 HealthCare Index
CUSIP 091937540
Number of Holdings as of Sep 30, 2019 96
Max Offer Price as of Oct 14, 2019 $61.15
Open to New Investors Yes
Turnover Percent as of Sep 30, 2019 39%

Portfolio Characteristics

Portfolio Characteristics

Average Market Cap (Millions) The average size of the securities the fund invests in. as of Sep 30, 2019 $ 83,761.1 M
R-Squared (3y) as of Sep 30, 2019 96.35
Beta (3y) as of Sep 30, 2019 0.96
Best 3-Month Return Over the Last 3 Years 3 months ending Sep 30, 2018 12.99%
Worst 3-Month Return Over the Last 3 Years 3 months ending Dec 31, 2018 -10.16%
Fund Standard Deviation (3y) as of Sep 30, 2019 13.56

This information must be preceded or accompanied by a current prospectus. For standardized performance, please see the Performance section above.

Ratings

Ratings

Morningstar Rating

Overall Morningstar Rating for Health Sciences Opportunities Fund, Class Inst, as of Sep 30, 2019 rated against 136 Health Funds.

Lipper Leader

 
Overall Lipper Leaders ratings based on an equal-weighted average of percentile ranks for each measure over 3-, 5-, and 10-year periods (if applicable) and do not take into account the effects of sales charges for these categories (Consistent Return, Preservation, Total Return, Expense, and Tax Efficiency) as of Aug 31, 2019 out of 96, 12,229, 96, 50 and 96 Funds, respectively in Lipper's Health/Biotech Funds classification.

Holdings

Holdings

as of Sep 30, 2019
Name Weight (%)
UNITEDHEALTH GROUP INC 7.25
ABBOTT LABORATORIES 6.41
BOSTON SCIENTIFIC CORPORATION 4.12
THERMO FISHER SCIENTIFIC INC 3.83
MEDTRONIC PLC 3.73
Name Weight (%)
STRYKER CORPORATION 3.71
MERCK & CO INC 3.31
EDWARDS LIFESCIENCES CORP 2.93
AMGEN INC 2.86
ZOETIS INC 2.74

Exposure Breakdowns

Exposure Breakdowns

as of Sep 30, 2019

% of Market Value

Type Fund Benchmark Net
as of Sep 30, 2019

% of Market Value

Type Fund Benchmark Net
as of Sep 30, 2019

% of Market Value

Type Fund Benchmark Net
as of Sep 30, 2019

% of Market Value

Type Fund Benchmark Net
Negative weightings may result from specific circumstances (including timing differences between trade and settle dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management.

Allocations are subject to change.

Portfolio Managers

Portfolio Managers

Erin Xie
Head of the Health Sciences team

  

Portfolio Manager

Literature

Literature

Loading fund documents...
No documents found
Checkout {{ translations['submit'][selectedAction] }} {{ responseMessage }} {{ warningMessage }} You have previously requested to be opted out of all BlackRock Literature Services emails. To subscribe, you must opt back in.